Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Gensci Regeneration Sciences Inc. (GNS) -- Ignore unavailable to you. Want to Upgrade?

To: Andras who wrote (201)	10/20/1999 11:02:00 AM
From: Jose Kranz	Read Replies (1) \| Respond to of 225

ANDRAS, NEWS OUT: GENSCI REGENERATION SCIENCES INC: Continued Revenue Growth / October 19, 1999 GENSCI REGENERATION SCIENCES INC ("GNS-T") - Continued Revenue Growth GenSci Regeneration Sciences Inc., The OrthoBiologics Company(TM), announced that revenue for the third quarter ended September 30, 1999 was approximately $8.2 million (US$5.4 million), a 69% increase, excluding the impact of foreign exchange rate fluctuations, over third quarter 1998 revenue of $5.0 million (US$3.2 million). Since launching DynaGraft in October 1997, this represents eight consecutive quarters of solid revenue growth. "We are continuing to experience great progress in our business," commented GenSci's President & Chief Operating Officer, James M. DeMesa, M.D. "Clinical performance of our products is excellent and our customer base of active hospital accounts has surpassed 1,400 across North America. The third quarters' growth, especially during the normally soft period for surgical procedures during July and August, reflects strongly on the quality and acceptance of our products and the efforts being put forward by our dedicated team and our spine sales partner, DePuy AcroMed. With the continued growth from our DynaGraft(TM) line, three new products now being introduced, and our expansion into new markets, we anticipate continued strong performance. The Company anticipates releasing its Q3 earnings before the middle of November." Orthobiologics is one of the fastest growth areas within orthopedics. In the two years since its market introduction, DynaGraft(TM) (GenSci's initial product line) has achieved significant market penetration in the demineralized bone matrix/bone-substitute market (a portion of the entire orthobiologics field). According to the Datamonitor 1999 Report on U.S. Bone Substitutes, factors such as an aging population, product innovation, and increased surgeon awareness should continue to fuel significant market growth. GenSci Regeneration Sciences Inc. is The OrthoBiologics Company(TM), focusing on innovative treatments for musculoskeletal repair, reconstruction, and regeneration. The company currently designs, develops, manufactures, and markets biotechnology products focused in the areas of orthopedics, neurosurgery, and oral maxillofacial surgery. Certain statements contained herein constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance or achievements of the company to be materially different from those expressed or implied. Forward-looking statements involve risks and uncertainties, including, but not limited to, such risks as are described in the company's annual report. TEL: (905) 629-7557 Jim Cooke or Louis G. Plourde INET: www.gensci.bc.ca Email: lplourde@gensci-regen.com